Chimerix
safety a | Chimerix
Company
Deck Type
Sector
Industry
Deck date
May 2023
Slide
13 of 41
Similar slides by Chimerix
See diffirences between slides (animation)
Investor Presentation
August 2023
safety | Chimerix
Investor Presentation
March 2023
safety nausea tam a a a dose modifications discontinuations uncommon and treatment related aes generally grades | Chimerix
Related slides by other companies
Nuvalent
Investor Presentation
April 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of phase treatment related adverse events in patient all treated patients no no treatment related no aes leading to dose reduction or discontinuation no treatment related fatigue alt increased ast increased myalgia grade grade any grade grade ses alt aint as aspartate source a doe serous ses i | Nuvalent
Alkermes
Investor Day
March 2021
safety profile of consistent with mechanism of action and artistry safety regimens selected declared as based on totality of data dose may offer additional flexibility in treating certain tumor types and or in combination settings in the future maximum tolerated doses for were determined to be and no additional toxicities were reported in combination with most commonly reported at chills pyrexia fatigue nausea lymphopenia injection site reactions ast alt increase are most frequently reported treatment related adverse events aes majority anticipated effects of administration transient majority grade in severity most frequent grade was no treatment related discontinuations or deaths safety profile was consistent with most frequent grade was ast alt increase patient no treatment related discontinuations or deaths at three reported at of and were manageable with either dose interruption discontinuation and or standard of care treatment atypical capillary leak syndrome without hypotension grade injection site reaction grade transient fatigue nausea vomiting grade treatment related adverse events dose limiting toxicities maximum tolerated dose recommended phase dose serious adverse event subcutaneous intravenous data as of mar alkermes | Alkermes
Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of phase no no treatment related no aes leading to dose reduction or discontinuation no treatment related dizziness treatment related adverse events in patient all treated patients nausea alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting including source a toxicity | Nuvalent
Nuvalent
Investor Presentation
January 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of in no no treatment related no aes leading to dose eduction or or discontinuation ion no treatment related dizziness treatment related adverse events in patient all treated patients fatigue alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting toxicity including source a a | Nuvalent
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
August 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights